Sanjay Mohan
Vanderbilt University/Ingram Cancer Center · Vanderbilt Medical Center · Vanderbilt-Ingram Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sanjay Mohan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05799079 · Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantSanjay Mohan · terminated · Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1NCT03955783 · Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic MalignanciesSanjay Mohan · completed · Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma · principal investigator
- Ph2NCT03238248 · Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsVanderbilt-Ingram Cancer Center · completed · Myelodysplastic Syndromes, Myeloproliferative Neoplasm · principal investigator
- Ph2NCT02658487 · Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid LeukemiaVanderbilt-Ingram Cancer Center · completed · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Clinical Protocol and Data ManagementP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Elizabeth J Davis · fiscal years 2014 to 2026Named on NCT02658487
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:23 UTC. The ranking covers the 200 most relevant of 64 PubMed records, and a shared surname and initials can bring in a namesake. All 64 on PubMed
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Sci Transl Med · 20171,608 citationsRCR 50.4
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.N Engl J Med · 2021970 citationsRCR 57.5
- 421 citationsRCR 41.7
- Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.Sci Transl Med · 2015415 citationsRCR 12.5
- Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.Clin Exp Immunol · 2015230 citationsRCR 7.0
- Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.Nat Cancer · 2024175 citationsRCR 20.1
- Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.J Clin Endocrinol Metab · 1999170 citationsRCR 4.4
- Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.Bone Marrow Transplant · 2021136 citationsRCR 8.7
- Effect of brief exercise on circulating insulin-like growth factor I.J Appl Physiol (1985) · 1994133 citationsRCR 4.8
- Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.Clin Cancer Res · 2014120 citationsRCR 3.2